Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New TAVI Head-To-Head: Sapien XT Vs. Surgery-Superior CoreValve

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences will bring its next-generation transcatheter aortic valve implant (TAVI) system, Sapien XT to the U.S. just in time to face the growing threat of competition from Medtronic’s CoreValve, which earned an expanded FDA indication for patients at high risk for surgery.

You may also be interested in...

US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk

The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.

Edwards Reports TAVR Sales Progress In U.S. And Abroad

Edwards Lifesciences reported 19 percent year-over-year growth in worldwide sales of its Sapien transcatheter aortic valve systems during the second quarter of 2014. The company cites the ongoing launch of the Sapien 3 system in Europe and Sapien XT in the U.S. as keys to continuing growth.

TAVR Evolution On Display At EuroPCR

Data on both new transcatheter aortic valve technologies and established TAVR devices were featured at this year’s EuroPCR meeting in Paris.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts